2 papers
q-bio.BM2025
Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2
Latent Labs Team, Henry Kenlay, Daniella Pretorius +15
Drug discovery has long sought computational systems capable of designing drug-like molecules directly: developable and non-immunogenic from the start. Here we introduce Latent-X2,…
q-bio.BM2025
Latent-X: An Atom-level Frontier Model for De Novo Protein Binder Design
Latent Labs Team, Alex Bridgland, Jonathan Crabbé +13
Traditional drug discovery relies on rounds of screening millions of candidate molecules with low success rates, making drug discovery time and resource intensive. To overcome this…